| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skovronsky Daniel |
SVP, CSO, and Pres. LRL |
• – – |
2019-10-25 |
4 |
B |
$108.61 |
$543,050 |
D/D |
5,000 |
75,818 |
2.74 |
- |
|
| Ricks David A |
President & CEO |
• • – |
2019-10-25 |
4 |
B |
$108.38 |
$500,174 |
D/D |
4,615 |
157,405 |
2.81 |
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-10-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,000 |
59,500 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-10-24 |
4 |
B |
$107.49 |
$200,039 |
D/D |
1,861 |
56,440 |
2.39 |
- |
|
| Walker Karen |
Director |
– • – |
2019-10-21 |
4/A |
A |
$107.91 |
$9,928 |
D/D |
92 |
1,147 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-10-21 |
4 |
A |
$107.91 |
$12,410 |
D/D |
115 |
1,170 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-10-21 |
4 |
A |
$107.91 |
$1,942 |
D/D |
18 |
54,579 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-10-21 |
4 |
A |
$107.91 |
$13,597 |
D/D |
126 |
9,338 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-10-21 |
4 |
A |
$107.91 |
$10,899 |
D/D |
101 |
44,950 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-09-20 |
4 |
AS |
$117.00 |
$526,500 |
D/D |
(4,500) |
33,806 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-09-20 |
4 |
S |
$116.17 |
$24,437,726 |
D/D |
(210,000) |
116,600,304 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-09-16 |
4 |
A |
$110.13 |
$1,982 |
D/D |
18 |
54,561 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-09-16 |
4 |
A |
$110.13 |
$12,445 |
D/D |
113 |
1,055 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-09-16 |
4 |
A |
$110.13 |
$13,546 |
D/D |
123 |
9,212 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-09-16 |
4 |
A |
$110.13 |
$10,903 |
D/D |
99 |
44,849 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2019-09-05 |
4 |
AS |
$115.00 |
$1,086,980 |
D/D |
(9,452) |
100,211 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-09-03 |
4 |
AS |
$112.91 |
$2,201,745 |
D/D |
(19,500) |
38,306 |
|
- |
|
| Jonsson Patrik |
SVP and Pres., Lilly Bio-MedsO |
• – – |
2019-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,377 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-08-19 |
4 |
A |
$112.53 |
$13,616 |
D/D |
121 |
9,038 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-08-19 |
4 |
A |
$112.53 |
$2,026 |
D/D |
18 |
54,481 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-08-19 |
4 |
A |
$112.53 |
$10,915 |
D/D |
97 |
44,494 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-08-19 |
4 |
A |
$112.53 |
$12,378 |
D/D |
110 |
937 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-07-15 |
4 |
A |
$108.47 |
$10,955 |
D/D |
101 |
44,397 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-07-15 |
4 |
A |
$108.47 |
$2,061 |
D/D |
19 |
54,463 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-07-15 |
4 |
A |
$108.47 |
$13,559 |
D/D |
125 |
8,917 |
|
- |
|
1437 Records found
|
|
Page 27 of 58 |
|
|
1.33 (0.16%) 
